This article reviews the natural biology of noninvasive bladder cancer and its management strategies while summarizing the most recent advances in the field.
INTRODUCTION
Bladder cancer will account for an estimated 74 000 new cancer diagnoses and 16 000 deaths in the United States in 2015 [1] . Nonmuscle invasive bladder cancer (NMIBC), characterized by its tendency to recur and in certain high-risk populations progress, represents a heterogeneous collection of diseases that remain difficult to treat. Most patients may be managed with bladder-sparing therapies, whereas some require timely cystectomy. Advancements in our understanding of tumor biology, endoscopic technology and intravesical therapy are promising but are overall slow to develop and leave significant room for improvement. This article will review the natural biology and recent updates in NMIBC management.
NATURAL BIOLOGY
NMIBC disease may range from low grade to high grade with lesions carcinoma in situ; (CIS), surface tumors (Ta) or lamina propria (T1) invasion, each with varying oncologic outcomes. An ongoing challenge in this disease is that 50-90% of patients experience recurrence [2] and up to one-third will progress [3] , necessitating accurate risk stratification.
Recurrent tumors are dangerous and some host factors have been correlated with negative outcomes. In a high-risk superficial bladder cancer population of over 7000 patients, nearly 40% recurred without progression, one-third progressed and over 12% experienced bladder cancer-related mortality [3] . Invasion into the lamina propria was the only factor predictive of recurrence, while risk of progression and mortality were associated with female sex, African-American race, undifferentiated grade, CIS and T stage.
Risk stratification
Biological aggressiveness is variable in NMIBC and treatment choices differ based on risk stratification. The European Organisation for Research and Treatment of Cancer (EORTC) risk tables and Spanish Urological Club for Oncological Treatment (CUETO) scoring model provide templates for defining risk categories in NMIBC [4, 5] . The EORTC study, based on data from seven trials, found that number of tumors, tumor size and prior recurrence predicted recurrence while progression was influenced by T stage and grade as well as the presence of CIS [4] . However, very few patients were treated with bacillus Calmette-Guerin (BCG) in this study. Therefore, CUETO developed a scoring model that evaluates short-term and long-term recurrence and progression risk in BCG-treated patients only, based on four trials involving over 1000 patients [5] . Sex, age, grade, tumor status, multiplicity and CIS predicted recurrence, while those same factors and T stage were associated with progression. However, Xylinas et al. [6] evaluated the accuracy of these scoring systems in a retrospective analysis and found that both models overestimated the risk of recurrence and progression. Newer, more accurate tools, perhaps incorporating biomarkers, are therefore clearly needed.
Risk stratification is utilized in the guidelines issued by the National Comprehensive Cancer Network (NCCN) [3] , European Association of Urology (EAU) [7] and American Urological Association (AUA) [8] (Table 1) . Of note is the recommendation for radical cystectomy among high-risk patients. According to the NCCN, radical cystectomy should be offered for high-grade, T1 disease and in patients with recurrent or persistent NMIBC following intravesical therapy [3] . Similarly, the EAU and AUA recommend radical cystectomy for high-risk, recurrent disease [7, 8] .
Although low-risk and high-risk tumors have been well delineated in the various guidelines, there is a paucity of data regarding the definition and optimal management of intermediate-risk NMIBC. Therefore, the International Bladder Cancer Group reviewed available evidence and proposed a treatment algorithm for patients with intermediate-risk disease [9] . Recurrent and/or multiple low-grade Ta tumors, which constitute 'intermediate risk', were stratified and treated according to factors such as tumor multiplicity, size more than 3 cm, timing of recurrence less than 1 year and frequency of recurrence more than 1 per year. The authors stressed the importance of individualizing patient management based on appropriate disease classification. One way of customizing care is through the use of molecular markers from voided urine or resected tissue, although consistent, strong evidence to recommend routine use is currently lacking. A promising marker, Ki-67, an indicator of cell proliferation, has recently been shown to significantly correlate with tumor progression and recurrence in NMIBC [10] .
Impact of tobacco use
Smoking remains the most important risk factor in the development of bladder cancer (www.cancer. org/cancer/bladdercancer/detailedguide/bladdercancer-risk-factors). Risk is greater with increased tobacco consumption and, in fact, the risk attributable to cigarette smoking has increased over time in the United States, perhaps reflecting changes in cigarette composition [11] or altered work or environmental-related exposures. Smoking cessation is known to decrease bladder cancer risk [11] .
KEY POINTS
Risk stratification is a key component in the management of NMIBC although available tools are imperfect. Molecular markers may prove beneficial for individualizing treatment and predicting tumor recurrence and progression.
Urologists are a vital source of information for patients regarding the association between smoking and bladder cancer, particularly among active smokers striving to quit.
Enhanced endoscopy using Cysview, NBI, OCT and CLE improves disease detection and has been a useful adjunct to standard WLC.
In selected patients with low-risk NMIBC, observation is increasingly recognized as a reasonable treatment strategy although additional prospective studies are needed. In a survey about smoking cessation published in 2010, only 20% of American urologists always provided this service, whereas the majority never counseled patients [12] . However, Bassett et al. [13] conducted a more recent survey from a stratified, random sample of bladder cancer survivors and found urologists to be an important source of information regarding the causal relationship between smoking and bladder cancer. Active smokers cited smoking as a risk factor more commonly than never smokers and more frequently implicated tobacco use in their own cancers.
DIAGNOSIS AND STAGING
Cystoscopy with transurethral resection (TUR) of all visible tumors remains the standard of care in the diagnosis, staging and treatment of bladder cancer. In patients with CIS or suspected muscle invasion, evaluation of the urethra is imperative. Repeat resection, especially in high-risk patients, is indicated given the known impact on tumor recurrence and progression [14, 15] . Also key is obtaining muscle and acquiring a thorough pathologic review, both of which have been shown to impact bladder cancerspecific survival for all tumor grades [16] .
Resection may be performed using monopolar or bipolar electrocautery. Venkatramani et al. [17] found there was no difference in complications, including bleeding, obturator reflex, operative time or hyponatremia, although the use of bipolar electrocautery resulted in decreased cautery artifact.
Enhanced endoscopy
Technology continues to improve and the development of photodynamic diagnosis using intravesical administration of specialized dyes has augmented the ability to find early recurrent NMIBC. Cysview (Photocure Inc., Princeton, New Jersey, USA), or 'Blue Light Cystoscopy', has been shown to detect significantly more Ta, T1 and CIS than the standard white light cystoscopy (WLC) [18] . Cysview is the most well studied of the novel technologies and repeat TUR for high-risk NMIBC has resulted in decreased tumor recurrence when compared with WLC [19, 20] . In addition, Cysview is safe [21] and cost-effective [18] .
Narrow-band imaging (NBI), which is Food and Drug Administration (FDA) approved for use in NMIBC, has been shown to better delineate bladder tumors because of increased visualization of the more highly vascularized neoplastic tissue [22] . A randomized controlled trial (RCT) comparing restaging NBI-TUR vs. conventional WLC restaging demonstrated decreased recurrence rate in 126 patients followed for 3 years in those randomized to the NBI [23] . A more recent randomized study by Herr [24 & ] showed significantly decreased early and late tumor recurrences at 2 years following second look TUR using NBI when compared with conventional WLC in patients with high-risk NMIBC.
Optical coherence tomography is a promising, emerging technology for several urologic cancers including bladder, prostate and kidney [25] . Highresolution, cross-sectional imaging is useful in the diagnosis and treatment of bladder cancer, although depth of penetration is limited (2 mm) and the procedure is time-consuming with a steep learning curve [26] [27] [28] .
Confocal laser endomicroscopy (CLE) also provides real-time, ultrahigh-resolution imaging and can be used for diagnosis of disease in other organ systems [28] . Images are obtained following the administration of intravenous fluorescein dye and placement of a fiber optic probe through the endoscope. CLE can differentiate low-grade from highgrade tumors making it a useful adjunct to WLC [29] . More recently, CLE has also shown promise in the diagnosis and management of upper tract urothelial carcinoma [30] . CLE is not yet FDA approved for bladder cancer, although it has been cleared for ophthalmic and gastrointestinal procedures.
INTRAVESICAL THERAPY
Intravesical therapy allows local delivery of high concentrations of therapeutic agents to eradicate remaining malignant cells following transurethral resection of bladder tumor and is also used prophylactically to induce a local immune response reducing the likelihood of future bladder tumor recurrence. The decision to use intravesical therapy is contingent upon patient risk factors and the probability of future bladder tumor recurrence. Several notable studies evaluating novel concepts in intravesical therapy have been published over the last year.
Regional hyperthermia
The synergistic effect of combining hyperthermia with chemotherapy or radiation has been exploited for the treatment of invasive sarcomas and pelvic tumors for years [31, 32] . More recently, uses of intravesical conductive and intracavitary hyperthermia for NMIBC have been reported [33] [34] [35] . The three techniques for regional hyperthermia in bladder cancer utilize 70-120 MHz antennas, intracavitary radiofrequency hyperthermia with a 916 MHz antenna and intravesical conductive therapy using a heated perfusate. Geijsen et al. [36 && ] reported their prospective experience with regional 70 MHz hyperthermia in patients with NMIBC. Twenty patients with intermediate-risk to high-risk disease were treated with intravesical mitomycin C (MMC; 40 mg) combined with regional hyperthermia in 6 weekly sessions followed by a maintenance period of 1 year. Fourteen patients completed the induction period and four dropped out because of toxicity. The 24-month recurrence-free survival rate was robust at 78%.
Response to bacillus Calmette-Guerin and cytokine levels
Previous studies evaluating predictors of a durable response to BCG have centered predominantly on tumor markers [37] . However, it is increasingly evident that a more important predictor of BCG response is the host immune system [38] . Kamat et al. [39] recently published the results of a prospective clinical trial evaluating 130 intermediaterisk and high-risk bladder cancer patients and developed a nomogram predicting the probability of recurrence based on changes in interleukin (IL)-2, IL-4, IL-8, IL-18, IL-1ra, tumor necrosis factor-related apoptosis-inducing ligand, interferon gamma, IL-12, and tumor necrosis factor alpha; they found this to be the best predictor of BCG response.
Bacillus Calmette-Guerin refractory disease
Intravesical gemcitabine with mitomycin C Many patients with recurrent, BCG-refractory highrisk NMIBC consider radical cystectomy, yet many others either refuse or are not medically fit. In these instances, further intravesical therapy should be considered. Emerging data have suggested that gemcitabine alone may be effective in the setting of BCG failure [40] [41] [42] . In a recent retrospective analysis of 27 patients, Cockerill et al. [43] report a favorable and durable recurrence-free survival (RFS) of 15.2 months. A multiinstitutional analysis for sequential intravesical gemcitabine with MMC found that patients with high-grade NMIBC or BCG-refractory disease had a 2-year RFS of nearly 40% [44] .
Sequential combination of mitomycin C and bacillus Calmette-Guerin A randomized prospective trial by Solsona et al. [45 && ] in patients with intermediate-risk and highrisk NMIBC found the sequential combination of MMC with BCG to be more effective but more toxic than BCG alone. The 5-year disease-free interval was significantly improved with combination therapy, and this was especially evident in patients with recurrent T1 tumors. However, given the significantly increased local toxicity experienced by the combination group, the authors suggest that only patients with recurrent T1 disease should be offered this therapy given that they have the highest likelihood of recurrence.
Intravesical docetaxel
Systemically administered docetaxel has some efficacy in metastatic bladder cancer leading investigators to posit whether locally administered docetaxel might improve outcomes, and several studies have evaluated its utility in the treatment of BCG-refractory NMIBC. A recent phase I clinical trial by Barlow et al. [46] studied 54 patients with 6 weekly instillations of intravesical docetaxel. An impressive 59% of patients achieved a complete response, with 18 going on to receive further maintenance therapy. The 5-year disease-specific and overall survival rates were 85 and 71%, respectively.
Mycobacterial cell wall extract
Because BCG is a live attenuated culture preparation of the Mycobacterium bovis bacillus, it can be associated with systemic side-effects, which on occasion can be quite severe. Mycobacterial cell wall extract (MCWE) from Mycobacterium phlei is comparable in composition to BCG but does not contain any live bacterial elements, and thus may lessen the risk of systemic toxicity. A multiinstitutional clinical trial evaluating the use of mycobacterial cell wall-DNA complex (MCC) -which is essentially MCWE without a mercury-based preservative called thiomersalin BCG-naive and BCG-refractory patients with CIS, showed a 46% complete response rate at 12 weeks [47] . After 18 months, almost one-third of these participants remained disease free. A phase III trial evaluating the 1-year disease-free survival rate of MCC among BCG-refractory, CIS or recurrent high-grade NMIBC is currently underway (ClinicalTrial.gov; no. NCT00406068). As novel techniques like MCC emerge and standard therapies are refined, we can anticipate additional prospective studies evaluating their clinical utility and hopefully yielding improved outcomes in NMIBC.
SURVEILLANCE AND FOLLOW-UP
Because low-risk tumors typically pose only a mild health risk to patients, observation of these low-risk bladder tumors may be a safe alternative. Soloway et al. [48] published the first report of patients with NMIBC for whom their primary treatment strategy was observation. In this retrospective review, 32 patients had their tumor recurrence managed expectantly for an average of 10 months from 1992 to 2002. All but three (7%) had low-grade noninvasive recurrences after their period of observation ended. No patients experienced progression to muscle invasion. Gofrit et al. [49] published a retrospective review in which they successfully observed 28 patients with low-risk NMIBC for an average of 13.5 months. Main reasons for terminating surveillance were the appearance of additional tumors (n ¼ 19), excessive tumor growth (n¼9) and hematuria (n¼1). All recurrent tumors were low grade and noninvasive. In a separate analysis of 22 patients managed expectantly, only two patients (9%) had evidence of progression after an average of 17 months [50] . Furthermore, Hernán-dez et al. [51] reported the successful observation of 64 patients with NMIBC for an average of 10.3 months and, while no patient progressed to muscle invasive disease, 6.5% of patients progressed to a higher stage and 16.2% to a higher grade. As compared with historical controls matched for clinical characteristics, the authors found no significant differences in progression rates. Although methodological limitations existed, this was the first and only prospective analysis of observation for low-risk bladder cancer. It should be noted, however, that the small sample size of these studies speaks to the highly selective nature of these patients selected for surveillance.
Taken together, observation of low-risk bladder cancer is increasingly recognized as a reasonable treatment strategy for patients who clearly have tumors that pose very little risk of harm. However, high-quality studies assessing if surveillance can reduce treatment-related morbidity and lower medical costs without compromising oncologic efficacy are lacking.
CONCLUSION
Although management of NMIBC continues to evolve, timely detection, appropriate risk stratification and individualized treatment remain crucial. Recent advances in endoscopic tumor detection, coupled with improved intravesical therapies, have helped tailor treatment. Smoking cessation plays a key role in tumor prevention and urologists are instrumental in relaying information to patients. Further, well-designed clinical trials are needed to enhance risk stratification and treatment options for those patients refractory to current therapy and those patients who may qualify for expectant management.
